← ANALYST RATINGS · TIPRANKS
Black Diamond Therapeutics (BDTX): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $10.33, the highest $14.00, the lowest $8.00. The average is +500.8% from the last price of $1.72.
Analyst ratings 8
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 → $2.00+33.3% | Hold | +16.3% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 → $1.50−25.0% | Hold | −12.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 → $1.50−25.0% | Hold | −12.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | −12.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Hold | −12.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 → $1.50−25.0% | Hold | −12.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Hold | −12.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | +16.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 | Hold | +16.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 | Hold | +16.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 | Hold | +16.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 | Hold | +16.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | +16.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $10.00 | Buy | +481.4% | Reiterated | 06.08.26on TipRanks Aug 7 03:35 | +7.4%next day +1.0% · 5 days +4.0% | ↗ |
| Sean McCutcheon★★★★★★★★★★#1382 · hits 43% · avg +39.7% | Raymond James | $11.00 | Buy | +539.5% | Reiterated | 06.08.26on TipRanks Aug 7 03:30 | +7.4%next day +1.0% · 5 days +4.0% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $14.00 | Buy | +714.0% | Reiterated | 06.08.26on TipRanks 08:50 | +7.4%next day +1.0% · 5 days +4.0% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $8.00 | Buy | +365.1% | Reiterated | 06.08.26on TipRanks 07:56 | +7.4%next day +1.0% · 5 days +4.0% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $8.00 | Buy | +365.1% | Reiterated | 06.08.26on TipRanks 07:00 | +7.4%next day +1.0% · 5 days +4.0% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $11.00 | Buy | +539.5% | Reiterated | 06.08.26on TipRanks 06:45 | +7.4%next day +1.0% · 5 days +4.0% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 05.08.26on TipRanks Aug 6 06:00 | +0.8%next day +7.4% · 5 days +17.0% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | — | Hold | — | Downgrade | 03.12.25on TipRanks 12:40 | −22.4%next day +0.7% · 5 days −1.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Black Diamond Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.33 at a price of $1.89 (+448.2%); now: $10.33 at $1.72 (+500.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 5 | 7 | 6 | 6 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.09 (from $-0.24 to $0.62). Last quarter: $-0.17.
Best top-analyst consensus in the sector · Healthcare
About Black Diamond Therapeutics
- CEO: Mark A. Velleca
- Employees: 21
- 245 First Street, Cambridge, MA, 02142, US
- www.blackdiamondtherapeutics.com
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 87 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗